inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma
Sehn, Laurie Helen, Hübel, Kai, Luminari, Stefano, Salar, Antonio, Wahlin, Bjorn E., Gopal, Ajay K., Bonnet, Christophe Marc, Paneesha, Shankara, Trneny, Marek, Mashegu, Hafsat Umar, Lihou, Christine Francis, Li, Di, Scholz, Christian W.
Published in JOURNAL OF CLINICAL ONCOLOGY (01.06.2022)
Published in JOURNAL OF CLINICAL ONCOLOGY (01.06.2022)
Get full text
Journal Article
Conference Proceeding
inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
Sehn, LH, Hubel, K, Luminari, S, Salar, A, Wahlin, BE, Gopal, AK, Bonnet, C, Paneesha, S, Trneny, M, Mashegu, H, Lihou, CF, Cheng, L, Scholz, CW
Published in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)
Get full text
Published in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)
Conference Proceeding